Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Abstract: In some aspects, the disclosure relates to single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: In certain aspects, the present invention provides novel ActRIIB variants (in a homomultimeric or heteromultimeric form), as well as compositions and methods for using those variants to treat an indication associated with undesired activity of one or more TGF?-superfamily ligands. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: A system for controlling viewing of multimedia is provided. The system includes an image capturing module captures images or videos of a user while viewing the multimedia. A mouth gesture identification module extracts facial features from the images captured of the user; identifies mouth gestures of the user based on the facial features extracted. A training module analyses the mouth gestures identified to determine parameters; builds a personalised support model for the user based on the parameters determined.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: Methods and apparatuses for improve data clock to reduce power consumption are presented. The apparatus includes a memory configured to receive a data clock from a host via a link and to synchronize the data clock with the host. The memory includes a clock tree buffer configured to toggle based on the data clock to capture write data or to output read data and a command decoder configured to detect a data clock suspend command while the data clock is synchronized between the host and the memory. The clock tree buffer is configured to disable toggling based on the data clock in response to the command decoder detecting the data clock suspend command. the host includes a memory controller configured to provide a data clock suspend command to the memory via the link while the data clock is synchronized between the host and the memory.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Abstract: In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

Abstract: In some aspects, the disclosure relates to ActRII antagonists and methods of using ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using an ActRII antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using an ActRII antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: An integrated approach for utilizing waste products of 2G bio-refineries to fractionate the lignin of high purity. The present invention also provides a method of recycling of two waste products (2-G ethanol residue as the substrate (LRBR) and fusel oil/synthetic fusel oil (SFO) as one of the solvent) of the biorefineries in a beneficial manner to fractionate the lignin of high purity. The present method of separating high purity lignin comprises fractioning extractive-free lignin rich residue with a solvent, wherein the solvent is a mixture of SFO/Fusel oil and Formic acid. An optimized ratio of waste fusel oil and formic acid gave more than >85% yields of high purity lignin.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: A circuit interrupter movable among ON, OFF, and TRIP positions includes a housing, a latch situated on the housing, a number of mechanisms situated on the housing, each mechanism of the number of mechanisms including a contact arm that is movable with respect to the housing, a set of separable contacts including a stationary contact and further including a movable contact situated on the contact arm, a handle, a pin, a first spring that extends between the contact arm and the handle in at least one of the OFF position and the ON position, a second spring that extends between the handle and the pin, and the pin being movable among a position engaged with the latch in at least one of the ON position and the OFF position and another position engaged with the handle in the TRIP position.

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.

Abstract: An example method of performing an upgrade operation for a distributed service in a virtualized computing system is described. The virtualized computing system includes a host cluster, the host cluster having hosts and a virtualization layer executing on hardware platforms of the hosts. The method includes: receiving, at a controller of the distributed service, a first upgrade operation from a user, the distributed service including the controller and a plurality of service engine groups, each of the plurality of service engine groups including a plurality of service engines; and performing, by the controller, the first upgrade operation on software of the controller exclusive of software of the service engines in each of the service engine groups, the software of the controller and the software of the plurality of service engines in each of the plurality of service engine groups executing in a plurality of hosts.

Abstract: A computer-implemented string based force component creation method for a three-dimensional (3D) printer that interacts with a three-dimensional (3D) printer that is installed in a printing apparatus and that prints an object, the method including attaching a string mechanism to the 3D printer, and creating a force component to support the 3D printer and the object via the string mechanism that is attached to the 3D printer.

Abstract: Disclosed are system 100 and method of energy efficient hot and cold water management. The system 100 comprises: a control unit 101 for dynamically controlling the functioning of the system 100; at least a water storage tank 102 with at least one of a water level sensor, at least a heating element 1021, at least a temperature sensor 1022 or any combination thereof; at least an auxiliary water storage tank 103 with at least one of a water level sensor, at least a temperature sensor 1032; at least a water mixer unit 105 having at least a temperature sensor 1051; a user interface unit 1012 for controlling and monitoring different parameters including temperature, water level, opening and closing of valves 108 and 109; and a power supply with power backup unit 104 for providing basic power for proper functioning of the system 100.

Abstract: This disclosure describes a memory cell array with enhanced read sensing margin. The memory cell array includes a write port and a read port being connected through first and second data storage lines. The memory cell array further includes multiple word lines and bit lines arranged in rows and columns such that the read port is coupled to a read word line, a read bit line, and a virtual ground. The read port includes a first transistor coupled to at least the read bit line and the virtual ground, a second transistor coupled to at least the first data storage line and the first transistor, a third transistor coupled to at least the second data storage line and the read word line, and a fourth transistor coupled at least the first data storage line and the read word line.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:T?RII heteromultimers comprising an ActRIIA polypeptide and a TfiRU polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:T?RII heteromultimer) may be used to treat various disorders or conditions.

Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.